CD276 and glioma: Our research found that the expression levels of six immune checkpoint inhibitors (B7-H3, CTLA4, LAG3, PD-1, PD-L1, and TIM3) were increased with the increase in MELK expression, and significant positive correlations have been found between MELK and these immune checkpoints in glioma.